Navitor Pharmaceuticals has appointed James Randall “Randy” Owen to serve as its chief medical officer, the same position he held at Acadia Pharmaceuticals. Owen’s experience also includes roles at Lundbeck, Abbott (NYSE: [[ticker:ABT]]), Merck (NYSE: [[ticker:MRK]]), and Bristol-Myers Squibb (NYSE: [[ticker:BMY]]). Cambridge, MA-based Navitor is developing drugs that target a cellular signaling pathway known as mTORC1 in order to treat age-related diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
